Arvinas (NASDAQ:ARVN) Stock Price Up 4% – Should You Buy?

Arvinas, Inc. (NASDAQ:ARVN)’s stock price rose 4% during mid-day trading on Thursday . The stock traded as high as $9.09 and last traded at $9.05. Approximately 849,142 shares were traded during trading, a decline of 8% from the average daily volume of 921,891 shares. The stock had previously closed at $8.70.

Analyst Upgrades and Downgrades

ARVN has been the subject of several analyst reports. Oppenheimer cut Arvinas from an “outperform” rating to a “market perform” rating in a research report on Tuesday, March 11th. BMO Capital Markets set a $20.00 target price on Arvinas and gave the company an “outperform” rating in a research report on Wednesday, March 12th. HC Wainwright reissued a “buy” rating and issued a $81.00 target price on shares of Arvinas in a research report on Tuesday, March 11th. Bank of America decreased their target price on Arvinas from $54.00 to $28.00 and set a “buy” rating for the company in a research report on Wednesday, March 12th. Finally, BTIG Research assumed coverage on Arvinas in a research report on Tuesday, December 10th. They issued a “buy” rating and a $69.00 target price for the company. Five equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $37.47.

Arvinas Stock Down 2.8 %

The stock has a 50 day simple moving average of $16.24 and a 200 day simple moving average of $21.29. The company has a market capitalization of $601.76 million, a price-to-earnings ratio of -3.16 and a beta of 1.95.

Arvinas (NASDAQ:ARVN) last issued its earnings results on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same period in the prior year, the company earned ($2.53) earnings per share. As a group, analysts forecast that Arvinas, Inc. will post -3.81 EPS for the current year.

Insider Activity

In related news, CEO John G. Houston sold 31,338 shares of the business’s stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $16.72, for a total transaction of $523,971.36. Following the sale, the chief executive officer now owns 1,157,480 shares of the company’s stock, valued at $19,353,065.60. The trade was a 2.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Noah Berkowitz sold 8,658 shares of the company’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.59, for a total value of $74,372.22. Following the completion of the transaction, the insider now directly owns 110,023 shares in the company, valued at $945,097.57. This represents a 7.30 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 50,230 shares of company stock valued at $769,402. Insiders own 5.23% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ARVN. GF Fund Management CO. LTD. purchased a new position in Arvinas during the 4th quarter worth approximately $28,000. KBC Group NV grew its position in Arvinas by 77.0% during the 4th quarter. KBC Group NV now owns 2,885 shares of the company’s stock worth $55,000 after purchasing an additional 1,255 shares in the last quarter. Quantbot Technologies LP grew its holdings in shares of Arvinas by 147.3% during the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock valued at $108,000 after acquiring an additional 2,601 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of Arvinas during the 4th quarter valued at $171,000. Finally, Tema Etfs LLC purchased a new position in shares of Arvinas during the 4th quarter valued at $227,000. Institutional investors own 95.19% of the company’s stock.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.